FIELD: biotechnology; medicine.
SUBSTANCE: invention reveals the possibility of using recombinant hyaluronan/proteoglycan binding protein 1 (HAPLN1) or the gene encoding it as part of a pharmaceutical composition for the treatment of chronic obstructive pulmonary disease (COPD).
EFFECT: obtaining a composition containing hyaluronan/proteoglycan-binding protein 1 for prevention or treatment of lung diseases.
5 cl, 2 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN CONTAINING A VERSION OF CCL3, AND USE THEREOF | 2017 |
|
RU2727715C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| ANTIBODY SPECIFICALLY BINDING TO PAUF PROTEIN, AND ITS USE | 2017 |
|
RU2735102C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE | 2018 |
|
RU2788124C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| STRAIN OF AKKERMANSIA MUCINIPHILA AND APPLICATION THEREOF | 2019 |
|
RU2777068C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT A FUSED PROTEIN IN WHICH A TUMOR-PENETRATING PEPTIDE AND AN ANTIANGIOGENIC AGENT ARE FUSED FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES | 2016 |
|
RU2727238C2 |
| CYCLIC PROTEIN CONTAINING NO CYSTEINE RESIDUES | 2008 |
|
RU2486196C2 |
